SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer.

TPS208 Background: Postop platinum-based CT improves outcomes in completely resected NSCLC with nodal involvement, (St II-IIIA). Standard adjuvant CT is still insufficient to provide optimal survival . Improvement could be obtained through better risk selection or customized therapy. mRNA BRCA1 levels are prognostic in early NSCLC (Rosell et al 2007) and could be a predictive marker for CT activity. BRCA1 expression level could acts as a differential modulator of CT. In advanced disease p with low BRCA1 benefit from cisplatin-doublets meanwhile p with high levels BRCA1 attained longer survival when were treated with taxanes (Rosell et al 2008). Pharmacogenomic customization is feasible in adjuvant setting due to tissue availability and timelines after surgery. Previous pilot trial p with high-expression levels treated with postoperative CT singel agent taxane do not showed inferior outcomes compared to the groups treated with cisplatin-doublets (Massuti et al 2009 WLCC). Methods: Phase III prospective ran...